Your search returned 3 results.

Results
	1.	Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. [electronic resource] by Rosak, C Standl, E Reblin, T Stammer, H Seidel, D K Producer: 20070426 In: International journal of clinical practice vol. 60 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. [electronic resource] by Rosenstock, J Chou, H S Matthaei, S Seidel, D K Hamann, A Producer: 20090504 In: Diabetes, obesity & metabolism vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Course of islet autoantibody titers during Ig-immunoadsorption in a patient with newly diagnosed type 1 diabetes. [electronic resource] by Seidel, D K Geiss, H C Donner, M G Ritter, M M Schwandt, P Koll, R A Standl, E Ziegler, A G Producer: 19981014 In: Journal of autoimmunity vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search